Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 39, showing 5 Applications out of 191 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/20/03/01   GlycoShig3
    A Phase 2a age descending study to investigate the safety and immunogenicity of the SF2a-TT15 synthetic carbohydrate-based conjugate vaccine against Shigella flexneri 2a in adult, children and infant target population in endemic countries.   
Principal Investigator(s)
1. Fredrick Kipyegon Sawe
Site(s) in Kenya
Kenya Medical Research Institute Walter Reed Project Kericho
 
Trial Status (not set!)
Protocol Date 13-01-2020
View

2.

ECCT/20/02/03   LNG 1.5mg for pericoital use
    A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg    
Principal Investigator(s)
1. Anne Mwihaki Macharia
Site(s) in Kenya
1. Nairobi County (Nairobi City county)
2. Kiambu County (Kiambu county)
 
Trial Status (not set!)
Protocol Date 25-02-2020
View

3.

ECCT/20/02/01   Pharm PrEP for AGYW
    Pilot evaluation of pharmacy-based pre-exposure prophylaxis (PrEP) delivery   
Principal Investigator(s)
1. Prof. Elizabeth Ann Bukusi
Site(s) in Kenya
KEMRI/CMR/RCTP Kisumu-Lumumba Sub-County Hospital
 
Trial Status Not yet recruiting
Protocol Date 19-09-2019
View

4.

ECCT/20/01/01   LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH
    A SEQUENTIAL, MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) FOR NON-SPECIALIST TREATMENT OF COMMON MENTAL DISORDERS IN KENYA: LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH (DAPPER) PROJECT (SMART-DAPPER)           
Principal Investigator(s)
1. Anne Muthoni Mathai
2. Susan Meffert
Site(s) in Kenya
Kisumu County Hospital
 
Trial Status (not set!)
Protocol Date 08-08-2019
View

5.

ECCT/19/11/06   Optimize LNG EC
    An Open Label Phase 2 Pharmarcokinetic Study to Evaluate Double - Dose Levonorgestrel Emergency Contraception in Combination withEfavirenz Based Antiretroviral Therapy or Rifampicin Containing Anti - Tuberculosis Therapy. A5375   
Principal Investigator(s)
1. Lucy Chepkurui Koech
Site(s) in Kenya
KEMRI/WRP Kericho
 
Trial Status Not yet recruiting
Protocol Date 04-09-2019
View